Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Wave Life Sci Ord Sh (WVE)

Wave Life Sci Ord Sh (WVE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,060,545
  • Shares Outstanding, K 152,520
  • Annual Sales, $ 113,310 K
  • Annual Income, $ -57,510 K
  • EBIT $ -84 M
  • EBITDA $ -74 M
  • 60-Month Beta -1.21
  • Price/Sales 18.19
  • Price/Cash Flow N/A
  • Price/Book 11.62

Options Overview Details

View History
  • Implied Volatility 84.49% ( -9.56%)
  • Historical Volatility 81.24%
  • IV Percentile 43%
  • IV Rank 31.59%
  • IV High 195.68% on 07/18/24
  • IV Low 33.14% on 05/20/24
  • Put/Call Vol Ratio 0.05
  • Today's Volume 1,529
  • Volume Avg (30-Day) 1,405
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 31,431
  • Open Int (30-Day) 18,314

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.18
  • Number of Estimates 6
  • High Estimate 0.10
  • Low Estimate -0.40
  • Prior Year -0.15
  • Growth Rate Est. (year over year) -20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.84 +5.22%
on 12/18/24
16.38 -17.54%
on 12/02/24
-0.75 (-5.26%)
since 11/20/24
3-Month
5.34 +153.00%
on 09/23/24
16.74 -19.27%
on 11/11/24
+7.83 (+137.85%)
since 09/20/24
52-Week
3.50 +286.00%
on 02/14/24
16.74 -19.27%
on 11/11/24
+8.71 (+181.46%)
since 12/20/23

Most Recent Stories

More News
Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

WVE : 13.51 (+2.43%)
Insider Sale: President and CEO of $WVE (WVE) Sells 50,000 Shares

PAUL BOLNO, the President and CEO of $WVE ($WVE), sold 50,000 shares of the company on 11-25-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 18.7% of their...

WVE : 13.51 (+2.43%)
Wave Life Sciences to Present at Upcoming Investor Conferences

WVE : 13.51 (+2.43%)
Wave Life Sciences CEO to Participate in Analyst-led Fireside Chat at Jefferies London Healthcare Conference

Wave Life Sciences CEO Paul Bolno will speak at the Jefferies London Healthcare Conference on November 20, 2024.Quiver AI SummaryWave Life Sciences Ltd. announced that CEO Paul Bolno will participate in...

WVE : 13.51 (+2.43%)
Wave Life Sciences to Present at Jefferies London Healthcare Conference

WVE : 13.51 (+2.43%)
Wave Life Sciences: Q3 Earnings Snapshot

Wave Life Sciences: Q3 Earnings Snapshot

WVE : 13.51 (+2.43%)
Wave Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update

WVE : 13.51 (+2.43%)
Wave Life Sciences Third Quarter 2024 Financial Results Scheduled for November 12, 2024

WVE : 13.51 (+2.43%)
Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs

WVE : 13.51 (+2.43%)
1 Brand-New Big Reason to Buy This Biotech Stock Right Now

This stock currently has a good balance of risk and potential rewards.

WVE : 13.51 (+2.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

WAVE Life Sciences Pte. Ltd. is a preclinical biopharmaceutical company. It designs, develops and commercializes nucleic acid therapeutic candidates for Huntington's disease, Duchenne muscular dystrophy and inflammatory bowel disease. Huntington's disease, the Company has programs targeting HTT SNP-1...

See More

Key Turning Points

3rd Resistance Point 14.85
2nd Resistance Point 14.35
1st Resistance Point 13.93
Last Price 13.51
1st Support Level 13.01
2nd Support Level 12.51
3rd Support Level 12.09

See More

52-Week High 16.74
Last Price 13.51
Fibonacci 61.8% 11.68
Fibonacci 50% 10.12
Fibonacci 38.2% 8.56
52-Week Low 3.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar